2nd Annual Michigan Liver Cancer Consortium (4/23/25)

Wednesday, April 23, 2025, 5:30 PM - 8:30 PM, Townsend Hotel (Birmingham), Birmingham, MI


AMA PRA Category 1 Credits™ (2.50 hours), Non-Physician Attendance (2.50 hours)

An interactive program to learn key updates in the evaluation and management of liver cancer and engage in active case discussions with local experts in the field. This is a multi-disciplinary program for physicians, APPs, nursing, and learners of all levels. Experts in Hepatobiliary Surgery, Medical Oncology, Hepatology, Interventional Radiology, Diagnostic Radiology, and Radiation Oncology from around the state will interact to discuss current up-to-date management strategies and challenges that clinicians face in the care of patients with liver cancer.

1. To understand the latest data and approved therapies for systemic therapy in hepatocellular carcinoma management.
2. To learn about locoregional therapies for treatment of liver cancer, and strategies to choose specific therapies.
3. To discuss when to consider combination therapy utilizing liver-directed treatment along with systemic therapy for improved outcomes.
4. To collaborate with colleagues at other local institutions and learn about available options for treatment of liver cancer and clinical trial options for patients.
5. To review the patient best suited for surgical resection and/or liver transplant for liver cancer.
6. To discuss current approaches to using radiation therapy for patients with hepatocellular carcinoma.
7. To understand the latest diagnosis and management strategies for cholangiocarcinoma and the multidisciplinary approach to care of this condition.
8. To learn the latest radiology interpretation of cross-sectional imaging after liver cancer therapies based on the LIRADS criteria updates.
9. To understand the expanded indications for liver transplant for liver cancer.

Henry Ford Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

 

DESIGNATION STATEMENT:

Henry Ford Health designates this live course for a maximum of 2.50 AMA PRA Category 1 Credit(s) TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

 

FACULTY/PLANNING COMMITTEE DISCLOSURE STATEMENT: 

 In compliance with the ACCME standards for Commercial Support, all individuals in a position to control/influence the content of this activity are required to disclose all financial interests of their own with any ACCME defined commercial interests for the past 24 months and/or non-FDA approved use of a drug or a device that is included in the presentation. All financial relationships have been mitigated prior to the commencement of the activity.

 

ACCESSIBILITY STATEMENT: 

Henry Ford Health provides qualified interpreters and other aids for Deaf, DeafBlind, and Hard-of-Hearing persons at no cost. To request assistance, contact the event coordinator: Tami O'Connor at [email protected]. Please allow a minimum of 3 days to process this request.

Cancellation Policy

Please send cancellation requests to [email protected].

Henry Ford Health Office of Continuing Medical Education reserves the right to cancel or postpone this program if necessary; in the event of cancellation, course fees will be fully refunded. We are not responsible for other costs incurred such as non-refundable airline tickets or hotel penalties.

The Henry Ford Health Office of Continuing Medical Education adheres to ACCME Criteria, Standards and Policies regarding industry support of continuing medical education. Disclosure of faculty and their commercial relationships will be made prior to the activity.

Mitigation of Relevant Financial Relationships

Henry Ford Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Wednesday, April 23, 2025